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Modiﬁed nucleoside triphosphates (NTPs) represent powerful building blocks to generate nucleic acids
with novel properties by enzymatic synthesis. We have recently demonstrated the access to 20-SeCH3-
uridine and 20-SeCH3-cytidine derivatized RNAs for applications in RNA crystallography, using the corre-
sponding nucleoside triphosphates and distinct mutants of T7 RNA polymerase. In the present note, we
introduce the chemical synthesis of the novel 20-methylseleno-20-deoxyadenosine and -guanosine 50-tri-
phosphates (20-SeCH3-ATP and 20-SeCH3-GTP) that represent further candidates for the enzymatic RNA
synthesis with engineered RNA polymerases.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
In recent years, selenium-modiﬁed RNA1,2 has been frequently
used as a powerful derivative for multiple anomalous dispersion
(MAD) phasing3,4 of X-ray crystallographic data. In particular, the
ribose 20-methylseleno (20-SeCH3) modiﬁcation has been thor-
oughly explored and was responsible for several important struc-
ture determinations of small RNAs (Fig. 1).5–7 Although 20-SeCH3-
RNA is readily available by chemical solid-phase synthesis, the
concomitant limitation with respect to the size of the RNA repre-
sents a drawback.8 To overcome this limitation, we have recently
demonstrated the efﬁcient enzymatic synthesis of 20-SeCH3-uri-
dine and 20-SeCH3-cytidine modiﬁed RNA using the corresponding
pyrimidine nucleoside triphosphates and mutants of T7 RNA
polymerase.9
In this short note, we introduce the synthesis of the novel 20-
methylseleno-20-deoxyribonucleoside triphosphates of adenosine
and guanosine (20-SeCH3-ATP and 20-SeCH3-GTP) that represent
further potential candidates for enzymatic RNA synthesis with
engineered RNA polymerases yet to be evolved or with known
polymerase mutants under optimized conditions.10 Moreover, 20-
SeCH3-ATP and 20-SeCH3-GTP are considered interesting analogues
to study ATP- and GTP-dependent regulation processes and signal
transduction pathways.
2. Results and discussion
Chemical synthesis is the method of choice for preparing large
quantities of nucleoside triphosphates compared to the enzymaticra).
-NC-ND license.preparation with nucleoside and nucleotide kinases,11 especially if
modiﬁed nucleosides are targeted, as herein. The ﬁrst chemical
synthesis of NTPs was accomplished in 1949,12 and ever since, di-
verse chemical approaches have been developed to effectively syn-
thesize nucleoside triphosphates.13–32 Due to the multiple
functionalities of nucleosides, protection and deprotection of sugar
hydroxyl and nucleobase amino groups has to be carefully consid-
ered in order to minimize the formation of by-products and
regioisomers. Although challenging, one-pot procedures using
minimally protected or completely unprotected nucleosides as
substrates receive high attention and are a matter of continuous
optimization.14–20,31,32 For the 50-triphosphate synthesis of the 20-
SeCH3 modiﬁed purine nucleosides we have decided for such a
strategy and focused on the minimally protected N6-acetyl-20-
methylseleno-20-deoxyadenosine 1 and N2-acetyl-20-methylse-
leno-20-deoxyguanosine 3 (Scheme 1) as the appropriate
precursors.
Precursor compound 1was prepared in seven steps according to
our previously published route for the synthesis of the correspond-
ing phosphoramidite building block for RNA solid-phaseFigure 1. Constitution of 20-methylseleno derivatized RNA (A) and 20-methylseleno
ribonucleoside triphosphates of adenosine and guanosine (B).
Scheme 1. Synthesis and 31P NMR spectra of the modiﬁed nucleoside triphosphates
2 and 4. Reaction conditions: (a) (i): 1.2 equiv POCl3, 1.2 equiv 1,8-bis(dimethyl-
amino)naphthaline in PO(OMe)3, 0 C, 2 h; (ii): 5 equiv (HNBu3)2H2P2O7, NBu3 in
DMF, 0 C, 10 min; (iii): 0.2 M TEAB, 30 min; (iv): H2O/NH3, room temperature,
2.5 h; (b) (i): 1.2 equiv POCl3, 1.2 equiv 1,8-bis(dimethylamino)naphthaline in
PO(OMe)3, 15 C, 30 min; (ii): 5 equiv (HNBu3)2H2P2O7, NBu3 in DMF, 15 C,
45 min; (iii): 0.2 M TEAB, 30 min; (iv): H2O/MeOH/NEt3, room temperature, 14 h.
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the 30- and 50-hydroxyl groups of adenosine using 1,3-dichloro-
1,1,3,3-tetraisopropyldisiloxane (TIPDSiCl2), followed by protec-
tion of the 20-hydroxyl group as trimethylsilyl ether and reaction
with acetyl chloride to furnish the N6-acetyl adenosine derivative.
Then, the trimethylsilyl group was cleaved by p-toluenesulfonic
acid. Triﬂation of the ribose 20-OH gave the corresponding acti-
vated intermediate which was converted into the arabino nucleo-
side in diastereoselective manner by treatment with potassium
triﬂuoroacetate and 18-crown-6-ether. After triﬂation of the arab-
inose 20-OH, the activated derivative was reacted with sodium
methyl selenide, producing the desired 20-methylseleno key dia-
stereomer in high yields. Deprotection of the TIPDS moiety pro-
ceeded straightforward using tetrabutylammonium ﬂuoride
(TBAF) and acetic acid and provided compound 1, the actual pre-
cursor for introducing the triphosphate group (Scheme 1A). Prepa-
ration of the 50-triphosphate was performed according to
Yoshikawa0s monophosphorylation using POCl3 with trimethyl-
phosphate in the presence of 1,8-bis(dimethylamino)naphthalene
(proton sponge).14 The resulting 20-SeCH3 adenosine 50-chloro-
phosphate intermediate was readily reacted with tris(tetra-n-butylammonium)hydrogenpyrophosphate along the lines of Lud-
wig and Ötvös.15,16 After ion-exchange chromatography, deprotec-
tion of the acetyl group and subsequent reversed-phase
puriﬁcation, the overall yield for the conversion of 1 into 50-tri-
phosphate 20-SeCH3 adenosine 2 amounted to 36%.
The guanosine derivative 3was prepared in seven steps accord-
ing to our previously published route for the synthesis of 20-SeCH3
guanosine phosphoramidite for RNA solid-phase synthesis.6 Simul-
taneous protection of the 30- and 50-hydroxyl groups of commer-
cially available 9-[D-arabinofuranosyl]guanine using 1,3-dichloro-
1,1,3,3-tetra-iso-propyldisiloxane (TIPDSiCl2) was followed by
treatmentwithacetic anhydride toyield amixtureofN2,20-O-diacet-
ylated and N2,N2,20-O-triacetylated nucleosides. After protection of
the guanine atO6with a (4-nitrophenyl)ethylmoiety underMitsun-
obu conditions, mild basic hydrolysis liberated the arabinose 20-hy-
droxyl groupwhile the guanineN2 remainedmonoacetylated. Then,
triﬂation of the 20-OH primed diastereoselective introduction of the
methylseleno group using sodium methylselenide. Subsequent
deprotection of the TIPDS moiety and simultaneous release of the
O6-(4-nitrophenyl)ethyl groupproceeded straightforwardusing tet-
rabutylammonium ﬂuoride (TBAF) and produced the desired pre-
cursor 3 in high yield (Scheme 1B). Preparation of the 5’-
triphosphate was performed according to Yoshikawa0s procedure
for monophosphorylation using POCl3 with trimethylphosphate in
the presence of proton sponge.14 Subsequently, the 20-SeCH3 guano-
sine 50-chlorophosphate intermediatewas reactedwith tris(tetra-n-
butylammonium)hydrogenpyrophosphate at low temperature
along the lines of Gillerman29 and Howorka.34 Ion-exchange chro-
matography, deprotection of the acetyl group and reversed-phase
puriﬁcation, resulted in an overall yield 40% for the transformation
of3 into highlypure50-triphosphate 20-SeCH3 guanosine4.Wemen-
tion that acetyl deprotection of the 20-SeCH3 guanosine 50-triphos-
phate in aqueous ammonia (as applied for deprotection of the 20-
SeCH3 adenosine 50-triphosphate) was incomplete, according to
analysis by reversed-phase-chromatography and NMR spectros-
copy. However, cleavage of the acetyl group proceeded quantita-
tively when conditions were changed to triethylamine in methanol
and water.
In summary, we have generated an efﬁcient protocol for the ac-
cess to 50-triphosphates of 20-SeCH3 adenosine and 20-SeCH3 gua-
nosine. These modiﬁed NTPs represent a solid foundation for our
ongoing efforts to engineer the corresponding RNA polymerases
by directed evolution based methods and computational protein
design.3. Experimental
3.1. General remarks
Chemical reagents and solventswere purchased from commercial
suppliers (Sigma–Aldrich) and used without further puriﬁcation. Or-
ganic solvents for reactions were dried overnight over freshly acti-
vated molecular sieves (4 Å). The reactions were carried out under
argon atmosphere. Ion exchange chromatography was performed
on a GE Healthcare Äktaprime system using a DEAE Sephadex A-25
(GE Healthcare) self-packed column (GE Healthcare, HR 16/10). The
LC separation was monitored by ultraviolet (UV) detection at
280 nm. Triethylammonium bicarbonate (TEAB) gradients of 0.05–
1.0 Mwere applied (ﬂow rate: 2 mL/min). Prior to separation the col-
umnwas equilibrated with 1 M TEAB buffer at room temperature for
1 h and subsequently rinsed with 0.05M TEAB buffer. Reverse phase
chromatography was performed on a GE Healthcare Äktaprime sys-
tem using a commercial Merck Lobar 310-25 LiChroprep RP-18 (40–
63 lm) column. The LC separation was monitored by ultraviolet
(UV) detection at 280 nm. Solvent systems: A: triethylammonium
2418 T. Santner et al. / Bioorg. Med. Chem. 20 (2012) 2416–2418acetate (TEAA) (50 mM, pH8), B: CH3CN. A linear gradient of 0–40% B
was applied, ﬂow rate 5 mL/min. 1H, 13C, and 31P NMR spectra were
recorded on Bruker 300 MHz and Bruker 600 MHz instruments. The
chemical shifts (d) are reported relative to tetramethylsilane (TMS)
and referenced to the residual proton signal of the deuterated solvent
D2O: 4.59 ppm for 1HNMR spectra; 31P chemical shifts are relative to
external85%phosphoricacidandwereassignedbasedoncomparison
to the literature.13,27,32 1Hand 13Cassignments arebasedonCOSYand
HSQC experiments. MS experiments were performed on a 7 Tesla
wide bore Fourier transform—ion cyclotron resonance (FT-ICR) mass
spectrometer (Bruker Daltronics) with an electrospray ion source.
Sampleswereanalyzed inthenegative-ionmode. Theyieldsof the tri-
phosphate products were determined by UV spectroscopy (IMPLEN
Nanophotometer) using the following extinction coefﬁcients: e
(ATP, 260 nm) 15300; e (GTP, 260 nm) 11700.
3.2. 20-Methylseleno-20-deoxyadenosine 50-triphosphate (2)
Compound133 (74 mg, 0.19 mmol)was coevaporatedwith anhy-
drous pyridine (2 mL) three times anddriedover P2O5 in adesiccator
for four hours. Trimethylphosphate (1.5 mL) and 1,8-bis(dimethyl-
amino)naphthalene (61 mg, 0.23 mmol) were added and the solu-
tion was cooled to 0 C. Then, phosphoryl chloride (22 lL,
0.23 mmol) was added dropwise. After 2 h at 0 C, a mixture of
0.5 M tris(tetrabutylammonium) hydrogen pyrophosphate in DMF
(1.9 mL) and tributylamine (0.19 mL) was added and stirred for
10 min at room temperature. Then, 0.2 M TEAB buffer (15 ml, pH
7.5) was added, stirring continued for 30 min, and the mixture was
evaporated to dryness. The residue was dissolved in a minimal vol-
ume of water and puriﬁed using ion-exchange-chromatography.
The product fraction was collected and evaporated, then dissolved
in H2O (7 mL) and saturated NH4OH solution (20 ml) and stirred
for two and a half hours at room temperature. Finally, compound 2
was puriﬁed using reversed-phase-chromatography and isolated
as triethylammonium salt (by lyophilization from TEAA containing
product fractions). Yield: 68.4 lmol as a white foam (36%). 1H
NMR (600 MHz, D2O): d 1.93 (s, 3H, SeCH3); 3.82 (dd, J = 5.5 Hz,
J = 9.2 Hz, 1H, H–C(20)) 4.27 (m, 2H; H1-C(50), H2-C(50)); 4.43 (m,
1H, H–C(40)); 4.74 (m, 1H, H–C(30)); 6.37 (d, J = 9.3 Hz, 1H, H–
C(10)); 8.27 (s, 1H, H–C(8)); 8.57 (s, 1H, H–C(2)) ppm. 13C NMR
(150 MHz, D2O): d 3.03 (SeCH3); 8.24 (NCH2CH3); 23.23 (CH3COO);
46.66 (NCH2CH3); 47.28 (C(20)); 65.76 (C(50)); 73.04 (C(30)); 85.79
(C(40)); 88.95 (C(10)); 140.16 (C(2); 149.12; 153.04 (C(8)); 155.68;
181.20; ppm. 31P NMR (121 MHz, D2O): d 10.01 (d, J = 19.6 Hz,
1P, Pc); 10.79 (d, J = 19.9 Hz, 1P, Pa); 22.62 (triplettoid,
J = 19.7 Hz, J = 19.9 Hz, 1P, Pb) ppm. ESI-HRMS (m/z): [MH] calcd
for C11H17N5O12P3Se, 583.92581; found 583.92581.
3.3. 20-Methylseleno-20-deoxyguanosine 50-triphosphate (4)
Compound 36 (71 mg, 0.18 mmol) was coevaporated with anhy-
drous pyridine (2 mL) three times and dried over P2O5 in a desicca-
tor for 4 h. Trimethylphosphate (1.5 mL) and 1,8-bis(dimeth-
ylamino)naphthalene (57 mg, 0.26 mmol) were added and the
solution was cooled to 15 C. Then, phosphoryl chloride (24 lL,
0.25 mmol) was added dropwise. After 30 min at 15 C, a mixture
of 0.5 M tris(tetrabutylammonium)hydrogen pyrophosphate in
DMF (1.6 mL) and tributylamine (0.13 mL) was added and stirred
for 45 min at room temperature. Then, 0.2 M TEAB buffer (16 ml,
pH 7.5) was added at room temperature, stirring was continued
for 30 min, and the mixture was evaporated to dryness. The resi-
due was dissolved in a minimal volume of water and puriﬁed using
ion-exchange-chromatography. The product fraction was collected
and evaporated and the residue was dissolved in H2O/MeOH/NEt3
(3 mL; 7/3/1) and stirred 14 h at room temperature. Compound 4
was ﬁnally puriﬁed using reversed-phase-chromatography andisolated as triethylammonium salt (by lyophilization from TEAA
containing product fractions). Yield: 71 lmol as a white foam
(40%). 1H NMR (500 MHz, D2O): d 1.69 (s, 3H, SeCH3); 4.06 (dd,
J = 4.5 Hz, J = 7.9 Hz, 1H, H–C(20)); 4.15 (m, 2H; H1-C(50), H2-
C(50)); 4.18 (m, 1H, H–C(40)); 4.60 (m, 1H, H–C(30)); 6.08 (d,
J = 9.3 Hz, 1H, H–C(10)); 8.06 (s, 1H, H–C(2)) ppm. 13C NMR
(150 MHz, D2O): d 2.96 (SeCH3); 8.27 (NCH2CH3); 23.11 (CH3COO);
46.70 (NCH2CH3); 45.97 (C(20)); 65.71 (C(50)); 73.03 (C(30)); 85.62
(C(40)); 89.35 (C(10)); 116.30; 138.10 (C(2); 151.90; 154.02;
158.95; 181.01 ppm. 31P NMR (121 MHz, D2O): d 10.21 (d,
J = 19.8 Hz, 1P, Pc); 10.71 (d, J = 20.1 Hz, 1P, Pa); 22.54 (triplet-
toid, J = 19.9 Hz, J = 19.9 Hz, 1P, Pb) ppm. ESI-HRMS (m/z): [MH]
calcd for C10H16N2O14P3Se, 599.92073; found 599.92043.Acknowledgments
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